Revolve Biotechnologies, Inc.

Biotech · Private

Near-infrared fluorescent proteins (iRFP Max) for deep tissue imaging in research and drug development

revolvebiotech.com →
Grants
$448K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · iRFP-Max: A novel infrared fluorescent protein for deep tissue imaging$448,212
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1686HUMAN CELL CO——
1687SYMBIOTIX BIOTHERAPIES, INC.——
1688AscentX Medical, Inc.—$3.3M
1689Revolve Biotechnologies, Inc.——
1690MPEX PHARMACEUTICALS, INC.——
1691iQure Pharma Inc.—$5.3M
1692MicroMGx, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.